Concord Biotech Limited announced that its board recommended a final dividend of Rs 7.55 per equity share for the financial year ended March 31, 2026. The dividend is proposed on equity shares with a face value of Re 1 each. The payout is subject to shareholder approval at the ensuing annual general meeting.
The board fixed July 24, 2026 as the record date for identifying shareholders eligible to receive the dividend. The recommendations were part of the decisions taken at the board meeting held on May 29, 2026, which had been previously scheduled and intimated to the exchanges on May 23, 2026.
The board approved the standalone audited financial results for the fourth quarter and full financial year ended March 31, 2026. The consolidated audited financial results for the same periods were also approved. The board also approved the standalone and consolidated audited financial statements and the directors' report for the financial year 2025-26.
The board appointed Mrs. Ekta Gupta as an Additional Independent Director, effective June 1, 2026, for a term of five consecutive years, subject to shareholder approval. Gupta holds an MBA in Finance from Cardiff University and serves as Director of Sanghi Polymers Private Limited. She began her career in finance with roles at Deutsche Bank and Financial Markets before moving into leadership positions across business enterprises.
The meeting commenced at 3:00 PM and concluded at 4:24 PM on May 29, 2026.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.